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Abstract 
BACKGROUND: Recent research has suggested that levodopa!carbidopa (L-dopa), an oral medication that 
is prescribed for Parkinson's disease, may be effective alternative to treating amblyopia. The goal of this 
study is to provide clinical protocols to determine whether oral L-dopa can be used to augment standard 
occlusion therapy to improve sensory function for amblyopic patients with or without strabismus and 
anomalous correspondence (AC). The study design is a single-masked and pseudo-randomized with 
control subjects. It was designed to have a 13 week duration period. Visual sensory function will be 
evaluated in terms of visual acuities, contrast sensitivity, level of stereopsis, and suppression behavior. 
Amblyopic patients will then be screened through a battery of tests to assess the presence and depth of 
anomalous correspondence. Patients were excluded if screening tests indicate a poor prognosis for 
binocular integration after occlusion therapy, and if subjects have any contraindication to L-dopa use. 
Although this study was originally designed with the intension of enrolling 30 amblyopic subjects, it was 
modified to be a study design and case report. 
CASE REPORT: A 67 year-old man came to Pacific University to improve the alignment of a longstanding 
Left exotropia and left hypotropia. Two months after strabismus surgery the patient began taking the 
combination drug L-dopa/ C-dopa to improve the sensory function of his visual system with the ultimate 
goal to sustain the improved ocular alignment achieved from the strabismus surgery. At the end of the 18 
week L-dopa trial the patient's acuities were relatively unchanged from pre-study levels. Minimal changes 
were also noted in contrast sensitivity as well as objective and subjective ocular alignment 
measurements. The subject didn't note any subjective improvement in vision. 
CONCLUSIONS: Patients that suffer from amblyopia, strabismus, and anamomalous correspondence 
often are challenging cases to manage for clinicians in terms of meeting patient goals or expectations. 
Our study focuses on an adjunctive therapy that may lead the way to provide a more beneficial outcome 
for these patients than standard occlusion therapy alone. It could allow for less aggressive approaches in 
vision therapy while reducing treatment time. It may also increase success rates in strabismus surgery 
and reduce the overall number of surgeries required to obtain ocular alignment. At the end of our clinical 
trial there was little change noted in the Pilot subject's visual acuity, contrast sensitivity and measured 
angle of strabismus. 
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ABSTRACT 
BACKGROUND: 
Recent research has suggested that levodopa!carbidopa (L-dopa), an oral medication that 
is prescribed for Parkinson's disease, may be effective alternative to treating amblyopia. 
The goal of this study is to provide clinical protocols to determine whether oral L-dopa 
can be used to augment standard occlusion therapy to improve sensory function for 
amblyopic patients with or without strabismus and anomalous correspondence (AC). 
The study design is a single-masked and pseudo-randomized with control subjects. It 
was designed to have a 1;) week duration period. Visual sensory function will be 
evaluated in terms of visual acuities, contrast sensitivity, level of stereopsis, and 
suppression behavior. Amblyopic patients will then be screened through a battery of tests 
to assess the presence and depth of anomalous correspondence. Patients were excluded if 
screening tests indicate a poor prognosis for binocular integration after occlusion therapy, 
and if subjects have any contraindication to L-dopa use. Although this study was 
originally designed with the intension of enrolling 30 amblyopic subjects, it was modified 
to be a study design and case report. 
CASE REPORT: 
A 67 year-old man came to Pacific University to improve the alignment of a longstanding 
Left exotropia and left hypotropia. Two months after strabismus surgery the patient 
began taking the combination drug L-dopa! C-dopa to improve the sensory function of 
his visual system with the ultimate goal to sustain the improved ocular alignment 
achieved from the strabismus surgery. At the end of the 18 week L-dopa trial the 
patient's acuities were relatively unchanged from pre-study levels. Minimal changes 
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were also noted in contrast sensitivity as well as objective and subjective ocular 
alignment measurements. The subject didn't note any subjective improvement in vision. 
CONCLUSIONS: 
Patients that suffer from amblyopia, strabismus, and anamomalous correspondence often 
are challenging cases to manage for clinicians in terms of meeting patient goals or 
expectations. Our study focuses on an adjunctive therapy that may lead the way to 
provide a more beneficial outcome for these patients than standard occlusion therapy 
alone. It could allow for less aggressive approaches in vision therapy while reducing 
treatment time. It may also increase success rates in strabismus surgery and reduce the 
overall number of surgeries required to obtain ocular alignment. At the end of our 
clinical trial there was little change noted in the Pilot subject's visual acuity, contrast 
sensitivity and measured angle of strabismus. 
Key Words: Amblyopia, Anomalous correspondence, strabismus, visual sensory 
function, occlusion therapy 
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Introduction: 
Amblyopia is a non-organic reduction in visual acuity (as well as other visual sensory 
functions) not correctable by refractive means and usually is the result of light or form 
deprivation, strabismus or uncorrected anisometropia in early childhood. Anomalous 
correspondence (AC) is a sensory adaptation that is generally thought to be a response 
ocular misalignment. It is thought to be a sensory defense mechanism against diplopia 
that preserves rudimentary binocular visual functions. Adult amblyopes and patients who 
have AC have a poorer prognosis with either surgery or vision therapy. Strabismic 
patients with dense amblyopia or AC typically require multiple surgeries to correct the 
strabismus. This arises often to poor sensory fusion status or suppression allowing the 
eyes to drift out of alignment after surgery. Thus, any improvement in the sensory 
system, i.e. acuity, contrast sensitivity, fusional ability or reduction in anomalous 
behavior will be of great benefit in the treatment of AC patients; it wil allow less 
aggressive approaches, shorter treatment time, and potentially fewer surgeries to obtain 
alignment. 
Recent research has suggested that levodopa/carbidopa (L-dopa), an oral medication that 
is prescribed for Parkinson's disease, may be effective in treating amblyopia in adults 
when administered in conjunction with occlusion therapy I-IO, 15-18• L-dopa is a precursor 
for the catecholamine dopamine, a neurotransmitter known to influence the visual system 
at the retina and at cortical levels. Carbidopa is a peripheral decarboxylase inhibitor that 
prevents the breakdown of levodopa at peripheral sites and allows more levodopa to cross 
the blood brain barrier. In studies L-dopa has improved visual acuity on average in the 
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amblyopic eye by two lines, and one-half line in the dominant eye as well as a decrease in 
suppression tendencies 1• All results to date indicate the visual function improvement is 
permanent to at least 6 months, although long-term results are not known. This recent 
and not widely known treatment could prove important for hard-to-correct older 
amblyopic as well as anomalous correspondence patients. 
The purpose of these testing protocols is to study the affects of L-dopa administration on 
the visual sensory functions of subjects with amblyopia and (or) anomalous 
correspondence. We hypothesize that patients who are undergoing occlusion therapy and 
have reached a plateau or are having difficulty with patching may be able to obtain 
additional sensory function improvement from addition ofL-dopa therapy. We will 
measure visual outcomes in terms ofvisual acuity, contrast sensitivity, suppression 
behavior, stereopsis, and level of anomalous correspondence (if present). lfthese 
clinical trial results indicated that the combination of L-dopa and occlusion will provide a 
more beneficial outcome than standard occlusion therapy alone, it would be of great 
benefit to this patient group. 
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Methods 
These are the original methods for the multi-center design that was intended to have 30 
subjects. The tests used for the experiment are standard optometric procedures with rare 
associated risks. These tests are commonly referenced in optometric texts, journal 
articles, and classroom lectures on binocular vision. The tests selected are divided into 
four categories: determination of fusion potential, evaluation of sensory function, 
qualifying tests for anomalous correspondence, and measuring tests for anomalous 
correspondence. 
To assess if bifoveal fusion potential is present, we used the Clement-Clarke 
Synoptophore and the random dot butterfly stereo acuity test. 
To measure sensory function we used the BVAT (Binocular Video Acuity Tester). This 
measured visual acuities, contrast sensitivities, level of distance stereopsis, suppression 
behavior, and measurement of crowding with and without control bars. 
The qualifying tests for anomalous correspondence include: BV AT acuity and sensitivity 
testing 2) Macular Integrity Tester (Haidinger's Brushes), 3) Visuoscopy, 4) Visagraph, 
and 5) Dissociated Red Lens Test. 
Tests for measurement of anomalous correspondence include: 1) Synoptophore (Major 
Amblyoscope), 2) Hering-Bielchowsky (HBAIT) as well as Brock-Givner After-Image 
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Tests, 3) Red-Green Glasses Anomalous Correspondence Test, 4) Worth 4-Dot Test and 
5) Bagolini Striated Lens test. 
The testing protocols are as follows: 
Testing for Determination of Fusion & Sensory Potential: 
Clement-Clarke Synoptophore to assess if bifoveal fusion potential is 
present12 
1. Present subject with first and second degree targets at the objective angle of 
deviation. 
2. Patient reports simultaneous perception if viewing a first degree target or if 
targets fuse easily into a single target with a second degree target. 
3. If the patient reports the two images appear to jump when overlapping of 
targets occurs this may indicate the presence of horror fusionis. 
Random-Dot Stereo Optical Butterfly Test 12 
1. Subject will wear polarized lenses. 
2. Stereo test will be conducted at 40cm. 
3. Subject views random dot butterfly test and highest level of subjective stereo 
acuity. 
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4. Stereo acuity will be recorded in arc seconds, or if suppression is present this 
was noted. 
Determination of Sensory Function: 
BVAT Acuity and Contrast Sensitivity Testing19 
1. Monocular and binocular acuities were taken at standard 6 meter testing 
distance under standard room illumination. 
2. Distance Stereopsis was tested by wirt stereo circles. 
3. Check for suppression was noted with liquid crystal goggles. 
4. Contrast Sensitivity 
Initial contrast sensitivity testing stimulus level is two lines above the 
previously determined BV AT best monocular acuity level. 
5. Crowding effect was tested with and without control bars for the best visual 
acuity. 
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Qualifying tests for Anomalous Correspondence: 
BV AT acuity and sensitivity testing19 
1. Data was used as measured above. 
Bernell Macular Integrity Tester and Trainer (MITT)11 
1. Testing was performed under dim conditions at 50 em monocularly. 
2. The non-amblyopic eye was tested first to demonstrate the appearance of 
the brushes. 
3. Subject was directed to look at a fixation point and perceive the rotating 
brushes. If they cannot appreciate the rotating brushes then a blue filter or 
blue lenses was placed before the subject. If the subject still wasn't able to 
appreciate the rotating brushes then fixation status in the amblyopic eye is not 
possible. 
4. The amblyopic eye is tested again by asking the subject to regard the fixation 
point and note where the brushes are seen. If the pointer and brushes are 
superimposed over the fixation target then the subject has central fixation. If 
the brushes and pointer are not over the fixation target it indicates eccentric 
fixation. To calculate the amount of eccentric fixation use the following 
fonnula: Eccentric fixation (prism diopters) = 100 x (separation in 
centimeters)/(test distance in meters). 
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Visuoscopy (Keeler Ophthalmoscope)13 
1. Occlude the preferred eye. 
2. Have patient look directly at center of projected pattern of reticule and hold 
fixation as steady as possible. 
3. Clinician objectively determines the positioning of the fovea with respect to 
the center of the reticule. 
4. In general the target reticule separation is 1 prism diopter magnitude. 
5. If the subject has eccentric fixation then the direction and magnitude is 
notated. 
6. The steadiness of fixation should be notated. If unsteady, the amplitude and 
type of oscillations should be documented. 
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Taylor Associates Visagraph2 Testing Protocol 20 
The visagraph2 will be used to note stability of fixation. 
1. Subject is directed to fixate at a center X for 10 seconds without any eye 
movement. The ability of the subject to do so will exhibit the level of control 
a subject has over his/her visual mechanism. 
2. The test will first be run monocularly with the good eye. 
3. Next run the test monocularly with the deviant eye. 
4. Finally the test will be run binocularly (if possible). 
Dissociated Red Lens Test 11 -12 
1. An objective distance cover test was performed and neutralized with prism 
bars at standard illumination over the patient's best-corrected lens. 
2. A red lens and 1 0-diopter base up prism are placed before the fixating eye 
while the patient views a light at 6 meters. 
3. Patient was asked to describe the position of the two lights. If no horizontal 
separation is present then the subjective angle is zero, and harmonious 
anomalous correspondence exists (if there is a strabismus present- verified by 
the douse test). 
4. If the patient has uncrossed diplopia base-out prisms were added until the red 
and white lights are vertically aligned. Base-in prisms were added for crossed 
diplopia. 
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5. If the amount and direction of prism necessary to align the lights vertically is 
commensurate with the objective angle, as measured with the alternating 
cover test with prisms at the same fixation distance with the same eye fixating, 
then normal correspondence exists. If they differ by more than 4 prism 
diopters then unharmonious correspondence exists. 
Tests for Measurement of Anomalous Correspondence: 
Synoptophore Test (Clement-Clarke) n-n 
1. Determine the status of retinal correspondence by measuring the objective 
angle. Superimposition of two first-degree targets is used. 
2. The target with the Clement-Clarke guard house (for instance) should be in 
front of the non-preferred eye and the target of the guard should be in front of 
the preferred eye. 
3. The preferred eye is locked in the ortho position. 
4. The examiner alternately turns the illumination of each target on and off while 
moving the tube of the deviated eye until the two im~ges are superimposed. 
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The absence of any fixation movement indicates that the objective angle has 
been obtained, as read off the scale on the instrument. 
5. The subjective angle is determined by having the patient move the tube before 
the deviating eye until the targets appear superimposed. 
6. If objective and subjective angles are equal this indicates normal 
correspondence. If objective and subjective angles are unequal by 4 prism 
diopters or more this indicates anomalous correspondence. 
7. A subjective setting of zero by a strabismic patient indicates harmonious AC, 
whereas a subjective setting between zero and the objective angles indicates 
unharmonious AC. 
8. Once the subjective angle has been determined and the targets are 
superimposed the retinal correspondence can be confirmed by briefly 
extinguishing the target before the preferred eye and watching for any 
movement of the other eye (Douse test). No movement indicates normal 
correspondence, and movement indicates A C. 
9. The objective angle that was previously determined is placed in the 
synoptophore such that both images are placed on the foveae. In the presence 
of normal correspondence, superimposition of the targets will occur. In AC 
diplopia is reported. Esotropic patients will perceive crossed images. 
Exotropic patients will perceive uncrossed images. 
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Hering Bielchowsky (HBAIT) & Brock-Givner After-Image Test (Wayne 
Engineering Flash Test Unit)11 
The Brock-Givner afterimage directly measures the angle of anomaly by using 
afterimages (Ais) to tag the visual direction of the foveae. 
1. Occlude the deviating eye and have the patient look at a central fixation point 
on a modified photoflash oriented horizontally. The central flash must be 
opaque to produce a small gap in the AI. Flash the unit. The resultant 
horizontal afterimage will tag the fovea, assuming that the patient was 
accurately fixating. 
2. Switch the occluder, and repeat the procedure, placing a vertical after image 
on the deviated eye. (Remember that EF will affect this portion of the test, 
and the measured angle of anomaly must be corrected.) 
3. Uncover both eyes and ask the patient whether both Ais are seen at the same 
time. If not, the examiner can have the patient blink quickly or strobe the 
room lights (by alternately lowering and raising the room illumination every 3 
seconds) to help the patient appreciate the Ais. 
4. Instruct the patient to fixate a small fixation point on a centimeter scale on a 
blank wall at a distance of 1m. The patient should report the horizontal AI 
centered over the fixation point. The negative AI is more reliable in routine 
testing than is the positive AI. The negative AI is seen in a lighted room and 
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the positive AI is seen in a darkened room. The patient is asked to pay 
attention to the negative AI as the room illumination is increased. 
5. Have the patient report where the vertical AI is positioned. The number on 
the scale will represent the angle of anomaly in prism diopters (Brock-Givner 
Test). 
Red-Green Glasses Anomalous Correspondence Test ll-Il 
1. Patient views an illuminated gray featureless screen at distance of 2 meters 
with red-green glasses. 
2. A patient with AC will report a split field, one side red and one side green 
3. A patient with normal retinal correspondence will report an appreciation of 
color fusion or luster. 
4. Patient may see only red or only green, indicating suppression. 
Worth 4-Dot Test ll-tl 
1. Testing is performed at 50 centimeters and/ or 6 meters. 
2. Patient wears red/ green glasses 
3. The presence of 4 dots in the presence of constant strabismus indicates a 
subjective angle of zero and harmonious anomalous correspondence. 
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4. The position of the eyes must be noted at the time fusion is reported. 
5. If the patient reports 5 dots simultaneously a subjective angle exists and prisms 
can be used to differentiate normal correspondence from anomalous 
correspondence. 
6. Normal correspondence is diagnosed if the lights are superimposed into 4, 
with prisms equal to the objective angle, and no movement is noted on 
unilateral cover (douse) test of the preferred eye. 
7. The diagnosis of unharmonious anomalous correspondence is made if a 
significantly different prism (more than 4 PD) allows superimposition and with 
that prism the unilateral cover test shows movement. 
Bagolini Striated Lenses (Bernell)12-13 
1. A Bagolini lens is placed in front of each eye with the striations 90 degrees 
apart. 
2. The patient views a penlight at 1 meter. 
2. The patient's vision of the test target is relatively unimpaired, and the light 
source appears as two streaks at right angles to each other. 
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3. The number of streaks and lights perceived (1 or 2) is noted. If only one 
streak is seen or if a missing section of a streak is noted then suppression is 
present. 
4. If the two streaks cross at the intersection of one light this indicates normal 
correspondence if no strabismic deviation is present. It indicates harmonious 
anomalous correspondence if a strabismic deviation is present. 
5. If one light is seen at the intersection of the two streaks then unilaterally cover 
the fixating eye (douse test). A corresponding movement of the deviant eye 
confirms the presence of AC. 
6. If two lights are seen above the intersection this indicates esotropia with 
normal correspondence. 
7. If the two lights are seen below the intersection of the two lines this indicates 
exotropia with normal correspondence. 
Selection of Subjects and Methods of Randomization: 
Subjects were recruited at three sites: Pacific University College of Optometry Family 
Vi;ion Center, Pediatric and Strabismus Referral Center in conjunction with Pacific 
University Portland Family Vision Center, and the office ofDr.Thomas Lenart at The 
Children's Eye Doctor. Subjects eligible for selection were intended to be amblyopic 
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who were age 4 or older. Subjects were allowed to enroll in the study if they did not 
meet any conditions in the exclusion criteria referenced below. 
Eligible subjects were intended to be randomly placed into three groups by a third party: 
1) control group who receive no therapy, 2) a group who uses occlusion therapy only and 
3) a group who uses oral L-dopa only. It was intended that a minimum of 30 subjects per 
group be enrolled to achieve statistical significance. 
Experimental Design 
The experiment design contained three phases. In the Phase I, the three groups of 
subjects were to be screened through the previously referenced battery of tests to obtain 
baseline sensory function ability and to indicate the presence and depth of anomalous 
correspondence. 
Baseline group index numbers were to be calculated for each of the sensory tests 
performed (see calculations methods in the results section). An anomalous 
correspondence index number was also to be calculated for each subject identified with 
AC, based on the number of positive results for each of the AC screening tests. These 
indices were to be compared to one another for the purposes of assessing effectiveness of 
the various therapies. 
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In Phase II data was to be gathered from the three test groups. All tests that were 
performed at baseline were to be retested at week 3.5 and week 7. 
Phase III was to involve a follow up visit 6 weeks after termination of therapy. During 
the follow up visit all tests that were performed at baseline were retested to assess the 
stability of any improvements in sensory functioning and or reduction in the angle of 
anomaly achieved at the end of phase II. 
Subjects in the occlusion therapy group were to have the non-amblyopic eye occluded for 
3 hours per day in the evenings for the 7-week period. They were to be given a brief 
questionnaire at each of the visits to determine the level of compliance (see forms 
appendix A). 
Subjects in the L-dopa therapy group were given L-dopa at the dosage of0.75 mg/kg 
body weight with 25% carbidopa three times per day after a meal or snack. (In Leguire' s 
studies subjects received L-dopa based on body weight and averaged 0.75 mg/kg body 
weight three times per day for 12 weeks). 1 This dosage is the same or about 25% less 
than that used in other previous L-dopa studies, and is known to be an effective and well-
tolerated dosage. Compliance with the drug regimen was strictly monitored by the 
prescribing physician when refilling the prescriptions. Our protocol required that 
subjects in the L-dopa group have a physical examination prior to beginning L-dopa 
therapy; weight, blood pressure, body temperature, heart rate and respiration rate be 
recorded to monitor for any health changes during the testing period. The patients were 
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responsible for the cost of the medications and the primary care physician's professional 
fees. 
The L-dopa dosage was based on body weight and was considered to be in the effective 
therapeutic range according to previous studies. 1-9 Subjects were instructed to take the 
individual dose with a meal or snack to minimize nausea and emesis. The liquid 
formulation was used in the present study to ease dosing requirements. Subjects were 
given two cans of Sustacal or Ensure, a high protein drink, and instructed to drink one 
can in the event of possible adverse side effects. Based on case reports, high protein 
substances (e.g., Sustacal) compete for transport with L-dopa in the gut and at the blood-
brain barrier, thereby reducing the pharmacodynamics of L-dopa and presumably the 
adverse side effects 5. Subjects were monitored for adverse effects to drug therapy at 
each subsequent testing visit or on an emergency basis. They were educated for signs 
and symptoms that may indicate an adverse drug reaction. In the event of an adverse 
drug reaction, subjects were advised to contact their primary care physician. 
Risks and Exclusion Criteria: 
Description of potential risks to subjects primarily entails discussing medical risks and 
visual risks. Other risks to the patient we will acknowledge include loss of 
confidentiality, and environmental risks from being present in an optometry office. In 
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recognition of the potential risks, we also employed measures to monitor the subjects and 
reduce risks. 
Medical risks involve the side effects of L-dopa. This drug is FDA approved and is 
currently used as a treatment of choice in Parkinson's patients. We will inform the 
subject that L-dopa is not typically used for subjects with amblyopia or anomalous 
correspondence. The use ofL-dopa for these patients is still considered experimental. 
Risks related to the L-dopa in decreasing prevalence include from data compiled by 
Leguire et al from 5 studies1-5: headache, tiredness, mood changes, nausea, dizziness, dry 
mouth, emesis (once per 1500 ingested capsules), restlessness, and nightmares. Other 
rare side effects are also noted. These rare side effects of L-dopa ingestion typically 
occur with much larger doses. As reported in the adult Parkinson's disease literature 14, 
they include: chewing, gnawing, involuntary movements, twisting, tongue or mouth 
movements, movements of feet hands or shoulders, muscle twitching, muscle jerks 
during sleep, hand tremors, various psychiatric disturbances, anxiety, memory loss, 
agitation, confusion, inability to sleep, mental depression, euphoria, gastrointestinal 
effects, loss of appetite, weight loss, and possible decreased white blood cell count. 
Leguire et al 1 have not observed any changes in the standard laboratory tests of the 41 
pediatric subjects tested to date. The above clinical adverse experiences occurring in 
1 percent or greater ofthe adult Parkinson's population is reference in Table 1, which 
will be provided to the patient in the Risk Disclosure document. We informed the subject 
that all the listed potential side effects are reversible with discontinuation of the use of L-
dopa. 
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The visual risks include intractable diplopia, horror fusionis, and unilateral diplopia. 
Intractable diplopia is a rare type of diplopia where the subject no longer exhibits 
suppression in the amblyopic eye and cannot achieve sensory fusion. Subjects were pre-
screened for some ability to achieve fusion before being accepted as a test subject. 
Minimizing intractable diplopia was achieved through exclusion of deeply embedded AC 
subjects as measured by the AC index, on a case-by-case basis. Horror fusionis is a rare 
and specific type of inability to fuse that is characterized by an avoidance ofbifoveal 
stimulation and an absence of suppression. Subjects were pre-screened for ability to 
achieve first-degree fusion before being accepted as a test subject. Subjects unable to 
achieve sensory fusion via the synoptophore may not be good candidates to participate in 
the study. These individuals may experience horror fusionis with L-dopa and binocular 
training therapy and will be excluded from the study. Unilateral diplopia is a side effect 
that may occur during therapy as the subject is trained to discontinue use of the 
anomalous correspondent point of the amblyopic eye. This is an expected and typically 
temporary phenomenon in AC subjects during foveal anti-suppression training. Diplopia 
problems were monitored by an optometric intern or faculty member at the Pacific 
University Family Vision Clinic. 
In order to protect confidentiality individual names of participants were not be disclosed 
to anyone outside ofthe investigators. In the event of publication of this study, the 
subject's identification will not be revealed. 
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If there are important new findings during the course of this study that might affect the 
subject's willingness to continue to participate, the investigators will immediately notify 
the subjects. Participation in this study is voluntary. The subject was able to refuse to 
take part in any part of the study or stop participation at any time. The subject was asked 
to notify the investigators immediately if he or she chose to discontinue participation in 
the study. 
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Limitations of the Methods Employed: 
Some of the limitations that could have been encountered from the methods employed in 
this study are as follows: 
• Patient non-compliance with use or dosage of medications: 
This is potentially a large source of variability in our study. In order to increase 
patient compliance for medication we have asked patients to fill out a survey form 
that questions their compliance with the dosing of the medication. (See appendix 
A for forms) 
• Patient non-compliance with occlusion therapy: 
This may also be a significant source of variability in the study. Patients were to 
be asked at each visit to complete a form that will assess their compliance with 
patching. 
• Clinician error in assessing objective tests: 
The nature of anomalous correspondence requires a fairly skilled clinician to 
correctly assess the presence and magnitude of AC. Skills in AC assessment can 
be variable from one clinician to another. 
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• Patient fatigue during testing: 
The entire battery of testing can be quite lengthy and patient fatigue is a factor 
that may limit the reliability of the data acquired. 
• Poor comprehension of testing instructions by patient: 
Amblyopia and AC testing is fairly complex and requires a subjects attention and 
understanding of the instructions to evoke good responses. Poor communication 
by the testing clinician can limit the validity of the data. 
• Inconsistent testing conditions: 
While we have attempted to give step-by-step instructions in order to maintain 
consistent testing methods, each clinic does have different resources and 
environments. This may come in the form of different equipment, different 
illumination, projector and chart differences, etc .... 
• Equipment error and calibration discrepancies: 
Different instrumentation may have given varying results. Instruments that are 
out of calibration may have yielded inaccurate results. 
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Results: 
Calculation Methods for Group Comparison: 
The results from the battery of tests performed on each of the subjects in the three 
experimental groups as follows: 
Visual acuity was taken by means of the BVAT (logmar) on all subjects for line as well 
as single letter acuity both with and without crowding bars. The best acuity level was to 
be averaged for each of the three groups (control group, occlusion therapy only group, 
and occlusion with L-dopa group). This was to be done at baseline visit (week 0), at 3.5 
weeks, 7 weeks and 13 weeks. 
Contrast Sensitivity was measured by the BV AT on all subjects using a test stimulous of 
two lines above threshold visual acuity. It was recorded monocularly as a percentage of 
BVAT full test stimulus contrast. This was to be averaged for each of the three groups 
and will be performed at the baseline visit (week 0), at 3.5 weeks, 7 weeks, and 13 weeks. 
Distance stereopsis was performed by the BV AT on all subjects and recorded in the 
lowest arc seconds visible to the subject. This was to be averaged for all subjects in each 
ofthe 3 groups. This was to be performed at week 0, 3.5, 7, and 13 
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Suppression was checked by means of the suppression checks built into the BVAT using 
the liquid crystal goggles and testing suppression of letters at various acuity demands. A 
value of+ 1.0 is given to subjects exhibiting suppression. A value of 0 is given to 
subjects who do not show suppression. For each group the sum of the values was to be 
calculated and divided by the subjects in the group. This will give a value of 1.0 if all 
subjects in a group suppress and a value of 0 if no subjects show suppression. This is 
multiplied by 100% to give percentage of subjects exhibiting suppression. 
Calculation of the anomalous correspondence index: 
It was intended that the anomalous correspondence index was to be calculated for each 
subject in each of the three groups. The AC index consist of results for each of the 
following tests: Synoptophore, Hering-Bielchowsky After-Image Test, The Worth 4-Dot 
Test and Bagolini Striated Lens Test. A positive AC response receives a value of the 
difference between the objective and subjective angles. An eso AC deviation receives a 
positive number and an exo AC deviation receives a negative number. The index score 
is the sum of the values corresponding to each test divided by the number of AC tests 
performed. This gives a score that measures both presence and magnitude of the angle of 
anomaly. All tests have equal weighting as far as the calculations of the AC index. 
The sum of each AC index for all subjects in a group was to be divided by the number of 
subjects in the corresponding group. This will give an average AC index value for each 
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of the three test groups, which was to be used for comparisons between groups and within 
groups. 
Comparisons were to be made from the above referenced data as follows: 
Mean group index data for both sensory function and AC was to be compared between 
the three groups at each time interval. A comparison was to be made at baseline (0 
weeks) 3.5 weeks, 7 weeks, and at 13 weeks. This data was to be compared by an 
analysis of variance (ANOVA) test using a two-tailed hypothesis with a p-value of ( 
<0.05). 
Mean intra-group comparisons was also to be made between baseline and 3.5 weeks, 
baseline and 7 weeks, and baseline and 13 weeks. A final comparison was to be made 
between 7 weeks and 13 weeks to assess stability after cessation of therapy. The data 
was to be analyzed with at-test comparison using a two-tailed hypothesis and a p-value 
of(<O .05). 
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Case Report 
Patient History 
A 67 year-old Caucasian male, FN, came to the Pacific University clinic with a chief 
concern of ocular misalignment for cosmetic reasons. He reported constant diplopia with 
symptoms of the left image interfering with the right image. The misalignment problem 
began over 20 years ago but the symptoms of the diplopia had become more noticeable 
over the previous year. FN had undergone strabismus surgery at age 19 for a left 
esotropia, afterwards the patient reported good cosmetic alignment. Subsequently he 
underwent a second strabismus surgery at age 67for a 551'. consecutive left exotropia and 
4t. left hypo tropia. He also reported using direct patching therapy of the right eye for 
three years in elementary school. FN wore bifocals full time for driving and for near 
work. 
Personal medical history includes hypertension of which is treated with an oral beta 
blocker. Otherwise he was in good health. 
Following vision therapy to improve peripheral fusion, FN inquired about the chance of 
improving visual acuity in the arnblyopic eye. He felt that he would be better able to fuse 
if the visual acuity was more equal. 
The patient was given several options and elected to try the L-dopa/ C-dopa therapy with 
a goal of improving both central and peripheral acuity. If successful this would improve 
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the long-term post-operative outcome of the most recent strabismus surgery, as good 
sensory fusion ability is essential in sustaining oculomotor alignment. 
Exam at Week 0 of L-dopa Trial 
Prior to entering the L-dopa/ carbadopa study, FN presented at the initial visit with 
habitual correction ofOD Pl - 1.00 x 140 add +2.25, OS +2.00 - 0.75 x 056 add +2.25 
giving BVAT distance line acuities of20/20 -l OD, 20/30 OS. He demonstrated no 
distance stereopsis with BVAT wirt circles, nor did he at near with the stereofly. 
Contrast sensitivity with BVAT using 2lines above best acuity was 25% for both OD, 
OS. 
All cover testing was performed without correction. Cover testing revealed that his post-
operative objective residual angle was measured at 3~ left esotropia, 1 0~ left hypotropia 
in primary gaze at distance with a dissociated vertical deviation (DVD). 
The crowding effect on acuity was tested also by BV AT giving 20/20 acuity OD for 
chart, line and letter. OS acuity was 20/30 chart, 20/25 -3 line, and 20/25 letter acuity. 
Visuoscopy was attempted but an assessment was unobtainable due to poor foveal light 
reflex and small pupil size. 
The dissociated red lens test objective angle was 1 0~ left hypotropia with no lateral 
movement, measured without correction. An estimation of the subjective angle was 
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placed at 411 left esotropia with 811 left hypotropia. With the objective prism in place the 
patient was unable to obtain fusion of the targets. 211 BO was placed in front of the 
patient and he reported the red and white lights had changed changed positions laterally 
but again no fusion was ever noted. 
Synoptophore testing yilrled an objective angle of 2 ~ left esotropia with 6~ left 
hypotropia. Subjective angle measured at 1011 left esotropia with 611 left hypotropia. The 
patient was able to achieve superimposition of first-degree targets briefly. This suggested 
he did not express horror fusionis. 
During the Worth 4-dot test the patient gave a response of 4 dots in the distance, with a 
constant vertical strabismus present. This may have suggested one of the dots was fused 
briefly. See figure 1-1. However at a test distance of 50 centimeters the patient reported 
5 dots. 
35 
f- OS 
· ( Luster 
• ~ - OD 
Figure 1-1 Worth Dot 
Bagolini Striated Lens test revealed constant diplopia as two lights were seen. A sketch 
by the patient is demonstrated in figure 1-2 representing the patient' s subjective 
perception. This suggested that FN was not suppressing either eye during binocular 
viewing. It also shows the presence of the left hypotropia. 
The combination drug L-dopa/ C-dopa was initiated with 1 dose per day for 3 days, then 
2 doses per day for 3 days, then 3 doses a day thereafter. 
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OS 
Patient's drawing of Bagolini percept_ 
Figur" 1-2 
Exam at Week 7 of L-dopa Trial 
At the start of the exam the patient was asked to complete a symptom check list. The 
patient reported one episode of dizziness, and an occasional flushed feeling. 
BV AT acuities were OD 20/20 chart, line and letter. OS was 20/30-2 line, and 20/20 -2 
single letter. 
Contrast sensitivity was again tested on the BV AT at two lines above best acuity. OD 
tested at 20%, OS at 25%. 
No distance or near stereopsis was obtainable with the BV AT or near stereofly. 
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Dissociated red lens test showed unsteady fixation with the objective angle measuring gil 
left hypotropia and no lateral movement. Subjective measure was gil to 11 il left 
hypotropia. The subject was unable to fuse the target and reported variations in the target 
position from slightly eso to slightly exo with only brief moments of fusion. 
Worth 4-Dot gave a subjective response of 5 dots seen at distance. See figure 1-
3. 
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Figure 1 - 3 
Bagolini striated lens test was given and the patient drew a similar picture of the striated 
image as in the initial exam, see figure 1-2. 
The patient continued taking the L-dopal C-dopa at 3 doses per day until the next 
scheduled exam. 
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Exam at Week 18 of L-dopa Trial 
The patient was again asked to complete a symptoms check list. The only side effect he 
reported was increased incidents of night dreams. 
BV AT acuities were OD 20/20 chart, line and letter. OS 20/30 line, 20/25 single letter 
acuity. BVAT contrast sensitivity was OD 25% and OS 32%, again using two lines 
above best recorded acuity. 
No distance or near stereopsis was achieved by the patient. 
Distance cover testing gave objective angle of gil left hypotropia with no lateral 
movement. Near cover test was gil left hypo tropia and 2il left esotropia. 
Dissociated red lens test gave a slight uncrossed diplopia response with no fusion ability 
with objective prism in place. Patient reported the subjective angle to be unstable and 
approximately the same as the objective finding. 
Synoptophore objective angle was measured at gil left hypotropia with 2illeft esotropia. 
Subjective angle was found to be 11"' left hypotropia and 7il left esotropia. The change 
from the week 0 subjective findings suggested a hypo direction shift in the patient's 
sensory perception may have occurred. 
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Worth 4-dot test showed 5 dots seen at both distance and near testing. The dots were 
dissociated and subjectively was reported as crossed indicating a subjective left exo and 
left hypo posture. See the figure 1-4 for the patient's perception ofthe test. 
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Figure 1 - oll 
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BV AT Contrast Sensitivity; two lines above threshold acuity 
Eye Tested WeekO Week 7 Week 18 
OD 25% 20% 25% 
OS 25% 25% 32% 
Measured Angle of Deviation via Synoptophore 
Type of Measure WeekO Week 7 Week 18 
Objective angle 2"' LET, 6'~LHoT not tested 2"' LET, 8"'LHoT 
Subjective angle 1 o"' LET, 6"'LHoT not tested 7"' LET, 11"' LHoT 
The overall result in the patient's best-corrected single letter acuity remained unchanged 
from before the L-dopa trial and at the end of the 18 week period. The patient did have a 
2-3 letter improvement noted at week 7 that was not repeatable by week 18. 
Contrast sensitivity also showed minimal change throughout the study with a slight 
improvement noted on the right eye at week 7. This improvement however was not 
repeatable at week 18. The left eye showed a slight decrease in overall contrast 
sensitivity from week 0 to week 18. Subjectively the patient did not notice any 
improvement in his vision. 
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Throughout the study the subject never demonstrated a measurable level of stereopsis via 
BVAT wirt circles at distance, nor titmus stereofly at near. 
The subject demonstrated characteristics of anomalous correspondence based on the 
difference in measured objective and subjective angles with the synoptophore as well as 
dissociated red lens tests. This remains inconclusive though, as an accurate measure of 
eccentric fixation was not obtained. In any case, the patient was only able to achieve a 
fleeting sensory fusion status at best throughout the 18 week period. The red lens, 
synoptophore and worth dot tests all showed an unstable motor and sensory system as 
well. 
The subject reported good compliance with dosing of the medication and throughout the 
study only reported mild side effects consisting mostly of increased dreaming at night. 
The original protocol of 13 weeks of taking the L-dopa was not followed as per the 
design of the study had intended because of scheduling difficulties encountered both with 
the patient and the principal examiners. 
Implications of the Results of the Study: 
This study was comprehensive in design with a goal of recruiting enough subjects to 
make statistical comparisons. Our original goal was to determine whether or not L-dopa 
could be used as an adjunctive therapy to standard occlusion treatment for amblyopic 
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patients with or without AC. Unfortunately we were only able to recruit only one 
experimental subject out of the three sites. It is hoped that future trial multi-center 
clinical trials will investigate the effects of L-dopa on sensory function. This novel oral 
medication-occlusion therapy approach may lead to changing the standard of care for 
patients suffering from amblyopia or anomalous correspondence. 
Limitations of the Results: 
Given the insufficient enrollment in this study, theoretical limitations of the results of this 
study could of arose from: 
• Assumptions that the test population is representative of the general population 
• Assumptions that responses from the test population can be generalized to the 
larger population 
• Assumption that increased foveal and peripheral sensitivity would decrease 
sessions required for vision therapy and surgeries required in strabismics. 
• Assumption that an improved sensory function would ameliorate the quality of 
life experienced by amblyopic patients. 
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Discussion: 
The study is comprehensive in design, and in theory was seeking to recruit enough 
subjects with amblyopia and anomalous correspondence, to allow significant statistical 
analysis of findings. Ultimately, the goal of this study was to determine whether L-dopa 
could be used to augment standard occlusion therapy for amblyopic and/or anomalous 
correspondence patients. Test results may in the future be part of a large multi-center 
clinical trial examining L-Dopa augmentation of occlusion therapy for amblyopia. 
Given only one experimental subject, we do not have sufficient data to either accept or 
reject the hypothesis of whether L-dopa is a useful adjunctive treatment in amblyopic or 
AC patients. We have presented the data we gathered from the one subject that enrolled 
in the L-dopa trial. The data from this subject are difficult to interpret as there were 
transient changes that occurred in the patient's sensory functioning during the trial. 
This paper focuses on the background research, design and planning required to conduct 
a clinical trial to measure effectivity of oral L-dopa on visual sensory functioning. We 
have learned from the various obstacles that were encountered during this investigation. 
The following is a summery of important points that we noted and our impressions as a 
guide for future researchers. 
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WE DID NOT GET ENOUGH PATIENTS FOR A STATISTICALLY SIGNIFICANT 
STUDY OWING TO THE RELATIVELY FEW NUMBERS OF PATIENTS WITH 
AMBLYOPIA AND ANOMALOUS CORRESPONDENCE IN THE GENERAL 
POPULATION WILLING TO PARTICIPATE IN THE STUDY. 
Historically occlusion therapy alone has not proved to be very successful with older 
children and adults. Because we were seeking to complete a statistically significant study 
on the use of L-dopa to augment occlusion therapy, we needed thirty patients per 
experimental group. Currently about 3% of children develop amblyopia (120,000/year in 
the USA) and many never regain normal vision in the amblyopic eye or regain binocular 
vision. Given the low frequency of amblyopes in the general population, and even 
smaller number of patients who have anomalous correspondence, the goal of producing a 
meaningful study in the given time allowance has presented a major challenge to 
investigators. For researchers interested in continuing with this study in the future, the 
task of promoting this type of study requires contacting clinicians in the fields of 
optometry, ophthalmology, pediatrics, learning disabilities, as well as recruiting subjects 
on university campuses. 
lt is the hope of the principal investigators that this study be continued by later groups of 
student investigators such that the results may yield information which can add to the 
current understanding of a combination L-dopa-occlusion-vision therapy treatment 
regime. Also, it is a possibility that other ophthalmologists and optometrists may have an 
interest in a multi-center clinical trial, which could add more useful information on our 
topic of interest. 
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DIFFICULTIES IN OBTAINING THE WRITTEN PRESCRIPTION FOR L-DOPA 
In this study we were only able to obtain data for one subject. We had at least two other 
subjects who were willing to participate in the study but we were unable to obtain a 
written prescription for the medication. The lead physician who was prescribing the L-
dopa discontinued his working relationship with Pacific University. He then became 
unable to write the L-dopa prescriptions for the patients who had agreed to become 
subjects in the study. A secondary physician was asked to become involved in the study 
and write the L-dopa prescriptions but was unable to due to his employment contract with 
a different university. It would have become necessary to file a new IRB (institutional 
review board) with the second university for him to become involved. This would have 
been too economically costly and time consuming. For future investigators it would be 
recommended to have a backup physician who understands the nature ofthe research and 
is comfortable in prescribing L-dopa. 
THE PRINCIPAL INVESTIGATORS WERE AWAY FROM THE LOCATIONS THAT 
WERE PARTICIPATING IN RECRUITING PATIENTS FOR THE STUDY. 
Patient recruitment requires active solicitation of patients, which became difficult for the 
principal investigators because of the clinic rotation nature of the fourth year of 
optometry school. At Pacific University the fourth year of optometry school requires 
rotation of clinic sites every 3 to 4 months. The principal investigators were away at 
preceptorship sites causing patient recruitment efforts to diminish for two thirds of 
clinical year. 
47 
USE OF ORALS MEDICATIONS IN AMBLYOPIA THERAPY IS STILL CONSIDERED 
EXPERIMENTAL AND PROVED TO BE AN OBSTACLE TO PATIENT ENROLLMENT 
IN THE STUDY. 
Patients generally were reluctant to join the study owing to the novel approach of using 
L-dopa for the treatment of amblyopia and strabismus. In spite of a significant amount of 
literature on the use of L-dopa for these patients, it is still considered an off label 
'experimental' use of the drug. For future researchers interested in this subject it will be 
important for the investigators of the study, and any other persons seeking to recruit 
patients for the clinical trials, to stress anticipated benefits for all those involved. L-dopa 
may potentiate vision therapy treatment as well as both the outcomes ofVT treatment and 
strabismus surgery. It is the belief of the investigators that improved sensory functioning 
in amblyopes will give these patients a better stimulus for fusion. This will reduce the 
number of vision therapy sessions as well as the number of strabismic surgeries required 
to achieve ocular alignment, and ultimately single binocular vision. This would be of 
great benefit to these patients as fewer office visits and fewer surgeries would thereby 
reduce health care costs. We would also like to inform future researchers that potential 
subjects should know that they will have the opportunity to contribute to our 
understanding of amblyopia, strabismus and anomalous correspondence. Their 
participation in this type of research helps pave the way to more efficacious treatments, 
as well as potentially change the current standard of care. Participants can meaningfully 
contribute to the advancement of optometric science and the general understanding of 
these difficult conditions. 
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THE VISUAL RISKS OF INTRACTABLE DIPLOPIA AND HORROR FUSIONIS IS 
ANOTHER DETERRANT TO PARTICIPATING IN THIS STUDY 
The visual risks subjects potentially encounter are significant deterrents to a patient's 
willingness to participate in this clinical trial. Currently, there is no guaranteed method 
of reversing horror fusionis or eliminating intractable diplopia (as its name suggests). 
Although these conditions are truly rare, patients need to be aware of their possibility and 
this can intimidate a subject from participation. 
THE EXPENSES REQUIRED FOR THE DRUG REGIMEN AND THE REQUIRED 
PHYSICAL EXAMS CAN LIMIT PATIENT PARTICIPATION 
The costs of the physical exam required before each subject can begin therapy may be 
prohibitive for some individuals. As mentioned before, it is required that we record 
weight, blood pressure, body temperature, heart rate and respiration to monitor any health 
changes during the testing period. In addition, as it is the patient's responsibility to cover 
the costs ofL-dopa therapy, this can prove to be discouraging from joining the study. To 
defray the costs of joining the study, we considered asking the drug manufacturer to 
donate the medication but determined any donations may place the integrity of the study 
in question. If a financial interest is involved in our study, it may cast doubts on the 
results upon peer review of the experiment. Additionally, if the patient must purchase the 
medications, he or she may feel more compelled to comply with the drug regimen. To 
promote the use of L-dopa to patients, we recommend to future investigators to inform 
potential subjects that the cost of repeated surgeries to correct regression of strabismus 
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would far outweigh the costs of the medications. Plus, the use of the oral medication has 
few side effects relative to the inherent risks of surgery. This approach may appeal to 
patients as well as parents considering surgical correction of strabismus in their children. 
THE OVERALL LENGTH OF THE STUDY EXCEEDED THE AMOUNT OF TIME 
AVAILABLE IN THE ACADEMIC CALENDER 
The study is a single-masked, controlled, pseudo-randomized 13-week longitudinal study. 
The study requires recruiting potential subjects, waiting for the results of the required 
physical exams before enrolling subjects in the study, and gathering data on all subjects 
all within the duration of an academic semester. Since patients may be selected for the 
study at different times, some data may not be available for results analysis. The problem 
arose in which completion of the study was not possible during two school semesters. It 
is recommended to future investigators to encourage subjects to schedule a physical 
examination as soon as they can and to plan for the time lag involved in scheduling and 
receiving the health report from the primary care physician. 
THE AMOUNT OF TESTS THAT WERE PLANNED FOR EACH PATIENT IN SOME 
CASES WAS IMPRACTICAL AND LEAD TO PATIENT FATIGUE 
Visual sensory functioning was to be evaluated in terms of visual acuities, contrast 
sensitivities, level of stereopsis, suppression behavior, and degree of crowding in all 
patients. Amblyopic patients will also be screened through a battery of several tests to 
assess the presence and depth of anomalous correspondence. Given the breadth of 
variables we are testing at each patient visit, a potential problem arose in which there was 
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not enough time allotted for completion of all the tests. Moreover, the patients who are 
amblyopic and strabismic often succumb to fatigue during the lengthy period of testing. 
Thus, it is recommended to future researchers to prepare an abbreviated list of tests that 
covers the important aspects of the study without excessive redundancy. This is 
especially pertinent in the cases where duration of testing is too long for the patient's 
attention span and comfort. 
THE STUDY, AS IS CURRENTLY BEING ADMINISTERED, MAY NOT PROVE 
BENEFICIAL IN OLDER SUBJECTS OR THOSE WHO'S SENSORY ADAPTATIONS 
ARE DEEPLY EMBEDDED. 
A possible source of problems in this study is the possibility of failure of L-dopa and 
occlusion therapy to improve visual sensory functioning if amblyopia and anomalous 
correspondence are deeply embedded. The experimental nature of L-dopa use in our 
study will likely require investigators to adjust the dosage levels of the drug. The current 
dosages and treatment periods used in our study were relatively accepted levels and 
durations; the dosages and time periods employed have been previously investigated, in 
particular by Leguire et al 1-9• We note that other researchers have begun to prescribe L-
dopa off-label in treatment of amblyopia. In brief, this drug combination ofL-
dopa/carbidopa is used in more than a dozen safely established studies and thousands of 
patients with Parkinson's disease. Not only do we expect changes to be made in L-dopa 
dosages for different patients, depending on factors such as age, duration of binocular 
problems, and health status and medications use, but we also expect to the treatment 
period to be altered as the use of L-dopa is researched further. In our trial the pilot 
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subject was 67 years old and there was minimal changes noted during L-dopa treatment 
period. It is difficult to say if the dosage was an important factor. In any case it appears 
that the longstanding nature of his visual sensory dysfunction proved to be a formidable 
obstacle in his treatment. 
FUTURE STUDIES MAY NEED TO REFINE OUR PROPOSED AC INDEX 
The AC index is calculated for each subject identified with AC, based on the number and 
magnitude of each of the screening tests. Then, each experimental group was to be 
assigned an AC index number based on the mean of all index numbers of the group 
members. These AC indices, which define the level of AC present in the group as a 
whole, were to be compared to one another for the purposes of assessing effectiveness of 
the various therapies. The AC index includes with it a certain degree of clinician error 
that needs to be recognized. It would be beneficial for future researchers to establish an 
accepted standard error for the proposed AC index as well as the individual component 
tests. The tests included in the AC index are common optometric clinical means for 
establishing the presence or absence for Anomalous Correspondence and the validity for 
these tests are assumed based on their use by clinicians working in this field. Future 
researchers could help establish which of the tests included in the AC index are the most 
efficient, reliable, and yield the most accurate results. 
52 
In conclusion, we have learned that it is a challenge to develop clinical trials which 
involve a very minor proportion of the general population, which may incur financial 
expenses for the patients, which carry threatening risks, and which require testing a large 
number of variables for an extended amount of time. Moreover, we have developed 
skills required to formulate comprehensive risk disclosure and informed consent 
documents as well as understanding the complexity of conditions such as amblyopia, 
strabismus, and anomalous correspondence. We feel that we have learned a great deal in 
understanding the procedures for diagnostic testing of these conditions. Finally, we have 
cultivated a deeper appreciation for the work of previous researchers who have laid the 
groundwork in innovative treatment approaches in the field of binocular vision, as well as 
for our project advisors whose deep knowledge base and circumspect minds have enabled 
us to cultivate our own understanding of treatment of patients with amblyopia and 
anomalous correspondence. 
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TABLE 1 - Clinical Adverse Experiences Occurring in 1% or Greater of Adult 
Parkinson's Patients 14 
Carbi~opa-
Advei;'.Se Experience Levodopa 
n=524 
I o/o-
,Dyskinesia 12.2 
Nausea 5.7 
Hallucinations 3.2 
Confusion 2.3 
'Dizziness 2.3 
Depression 1.3 
Urinary tract inJection 2.3 
Headache L9 
Dream abnormalities- 0.8 
Dystonia 0.8 
I Vomiting 1.9 
Upper tc~pirMbry 1.0 irifection 
Dyspnea 0.4 
'On-Ofl'phetfumena 1.1 
Back pain 0.6 
rtJry Mouth 1.1 
Anorexia 1.1 
Diarrhea 0.6 
~somnia 1.0 
Orthostatic 1.1 hypotension 
Shoulder pain 0.6 
,Chest pain 0.8 
, !Muscle cramps 1.0 
~aresthesia 1.1 
Urinary frequency 1.1 
·Dyspepsia . 1.1 
Constipation 1.5 
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Appendix A- Forms 
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Sinemet Subject Information Sheet 
(Please print or type) 
Patient Name: Date: 
-------------------------------
---------
Parent Name(s): ________ ______ _ 
Address: 
Home Phone Number: 
------------------------(with area code) 
Work Phone Number: 
------------------------(with area code) 
Eye Doctor's Name: ______________________ __ 
Patient Birth Date: 
-------------------------
Patient's Gender: 
-------------------------
Patient's Weight (Kg) _________ _ _ 
Type of Amblyopia: ___________ _ 
Best Corrected Visual Acuity at Baseline: OD: OS : ______ _ 
Best Corrective Lens, if applicable: OD: _________ _ 
OS: _________ _ 
Notes: 
--------------------------------------------
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SYMPTOM CHECKLIST 
Patient Name: Date 
------------------------- --------------------
Visit# Week Do, 03, 07, 013 (Check week visit) 
Comments: 
--------------------------------------------------
Please check Y(Yes) or N(No) for each symptom you experienced 
Muscle cramps OY ON Eating problems (anorexic) OY ON 
Diarrhea OY ON Ringing in ears DY ON 
Tiredness OY ON Confusion DY ON 
Nausea OY ON Depression DY .ON 
Vomiting OY ON Urinary problems DY ON 
Dizziness OY ON Walking problems OY ON 
Faintness OY ON Breathing problems OY ON 
Shaking OY ON Chest pain DY ON 
Twitching OY ON Back pain DY ON 
Dry Mouth DY ON Constipation DY ON 
Headache OY ON Eye lid twitch DY ON 
Numbness DY ON Muscle spasms DY ON 
Flushing DY ON Other (please be specific) 
Circles under eyes DY ON 
Restless sleep OY ON 
Nightmares DY ON 
Mood changes DY ON 
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SINEMET STUDY CHECKLIST 
D Subject qualifies for study (see exclusion criteria appendix B of Risk Disclosure) 
0 Obtained signed consent. Give subject or parent one copy of consent and 
signature page 
0 Physical exam completed by primary care physician 
D Weigh subject, without shoes, in kgs. Weight: ____ _ 
0 Fill out patient information sheet (needed for randomization). 
D Have Dr. Lenart si&111 Sinemet prescription 
D Have subject fill-out symptom checklist during visit at week number 0, 3, 7, 13 
0 Have subject fill out lazy eye questionnaire during visit at week number 0,3,7,13 
D Give subject or parent 2 cans of Sustacal (free refills if needed) 
D Give subject or parent a box of patches for each week (free refills as needed) 
0 Have subject return bottle with remaining Sinemet, if any, at their 7-week 
appointment. 
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AMBLYOPIA QUESTIONNAIRE 
PARTICIPANT NAME: DATE: 
---------------------------
---------
DATE OF BIRTH: ______ _ SEX: OM OF 
1. How many hours each day arc you supposed to wear your 
patch? __________ _ 
2. How many hours each day do you actually wear the patch? ________ __ 
Questions 3-8 are only applicable if the subject is a child 
3. How difficult is it to put on your child's eye patch? (circle one) 
1 2 3 4 5 6 7 8 9 10 
easy average extremely difficult 
4. How difficult is it to keep your child from removing their eye patch? (circle 
one) 
1 2 3 4 5 6 7 8 9 10 
easy average extremely difficult 
5. Does your child's behavior change when he or she is wearing the eye patch? If 
it does, please explain how it changes: 
6. How have other children reacted when your child is wearing the eye patch? 
7. Has your child's performance at school changed since patching has begun? If 
so, how has it changed? ------------------------------------
8. What have you tried in order to keep the eye patch on your child? 
9. Any other comments you would like to make? 
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SINEMET STUDY DATA SHEET 
Name: _____________ _ Date: 
Week#: (0, 3, 7, 13) _____ _ 
BVAT: 
Visual Acuities OD OS ou 
----- ------ -----
Single Letter Acuity: OD _____ OS _____ OU _____ _ 
Distance Stereopsis: _____ _ 
Distance Suppression: _____ _ 
Contrast Sensitivity: (use 2lines above best acuity, start supra-threshold) 
OD ______________ _ OS __________ __ 
VISA GRAPH: 
StabilityofFixation: OD: OS: OU: _____ _ 
Rate: Good fixation (0 deviations), Moderate fixation stability (1-2 deviations), 
Unstable fixation (>2 deviations) 
Macular Integrity Tester: 
Central Fixation: DY 
Eccentric Fixation: DY 
Visuoscopy: 
ON 
ON 
Eccentric Fixation: DY 0 N 
If yes prism diopters of eccentricity 
Objective Estimate of deviation (prism diopters): ______ NT S I 
Dissociated Red Lens Test: 
Distance cover test objective neutralization value (prism diopters): _ ____ _ 
Subjective response to red lens: Targets overlap: 0 Y 0 N 
Crossed diplopia 0 
Uncrossed diplopia: D 
Harmonious AC (objective cover test angle equals subjective) 
Unharmonious AC (objective angle differs from subjective by more than 4 prism 
diopters). 
Results: Harmonious AC : 0 
Unharmonious AC: 0 
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Hering Bielchowsky After-Image Test: 
Subjective vertical after-image report: _______ em 
Direction of angle of anomaly D Crossed Dun crossed 
Synoptophore: 
Superimposition of 1st degree targets achieved: OY ON 
Objective angle of 1st degree fusion: _____ _, rism diopters 
Subjective angle of 1st degree fusion: _____ _rrism diopters 
(if objective angle equals subjective angle this indicates normal correspondence. If 
objective and subjective angles differ by more than 411 this indicates AC) 
Red Green Glasses AC Test 
Subject Reports: Luster DY ON indicates normal correspondence 
Split field OY ON (one side red, one side green) indicates AC 
Sees Only 1 Color OY ON (indicates suppression) 
Worth 4-Dot Test 
Constant Strabismus present: OY ON 
Number of Dots seen: 02 03 04 05 OOther 
---
With neutralization of strabismus using the objective amount of prism: 
How many dots are seen: 02 03 04 05 00ther __ _ 
Distance at which subject was tested: _ __ _ 
Bagolini Striated Lenses 
Are 45 & 135 degree lines continuous: OY 
Are there missing segments in either line: OY 
If yes which line: 0135 045 
How many lights are seen: Ot 02 
If two, where are the lights relative to the intersection of the two lines: 
0Above 0Below 
Have subject sketch if necessary what is seen by patient 
Random Dot Butterfly Stereo Acuity Test at 40 em 
Highest Level of Stereo acuity seen arc seconds 
----
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